Vemircopan – Talk Bio

Actionable Insights Powered by AI

AstraZeneca Discontinues Vemircopan, Takes $753M Charge on Former Alexion Asset

AstraZeneca, Alexion, vemircopan, complement inhibitor, drug discontinuation, impairment charge, rare diseases, pharmaceutical industry